<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mankind Pharma Ltd — News on 6ix</title>
<link>https://6ix.com/company/mankind-pharma-ltd</link>
<description>Latest news and press releases for Mankind Pharma Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 18 Mar 2026 14:00:18 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mankind-pharma-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Press Release Mar 18 2026</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-mar-18-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-mar-18-2026-2</guid>
<pubDate>Wed, 18 Mar 2026 14:00:18 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Mankind Pharma acquires Rivotril brand for India, reinforcing focus on chronic CNS therapies".</description>
</item>
<item>
<title>Press Release Feb 03 2026</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-feb-03-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-feb-03-2026-6</guid>
<pubDate>Tue, 03 Feb 2026 21:19:51 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "Financial Results Q3FY26".</description>
</item>
<item>
<title>Actimed Therapeutics Announces Important Licensing Agreement with Mankind Pharma</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/actimed-therapeutics-announces-important-licensing-agreement-with-mankind-pharma</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/actimed-therapeutics-announces-important-licensing-agreement-with-mankind-pharma</guid>
<pubDate>Fri, 21 Nov 2025 10:29:00 GMT</pubDate>
<description>Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South AsiaRepresents a major step in the mission of Actimed to bring the first globally approved cancer cachexia product to patients in need London, UK – 21st Novemeber 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, today ann</description>
</item>
<item>
<title>Press Release Nov 06 2025</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-nov-06-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-nov-06-2025-6</guid>
<pubDate>Thu, 06 Nov 2025 21:43:28 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Press Release for Q2FY26".</description>
</item>
<item>
<title>Press Release Jul 31 2025</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-jul-31-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-jul-31-2025-4</guid>
<pubDate>Thu, 31 Jul 2025 21:57:35 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated July 31, 2025, titled "Please find attached Press Release".</description>
</item>
<item>
<title>Press Release May 21 2025</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-may-21-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-may-21-2025-2</guid>
<pubDate>Wed, 21 May 2025 21:59:49 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated May 21, 2025, titled "Press Release Q4FY25".</description>
</item>
<item>
<title>Press Release Jan 23 2025</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-jan-23-2025</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-jan-23-2025</guid>
<pubDate>Fri, 24 Jan 2025 00:52:39 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated January 23, 2025, titled "Press Release on Financial Results of the Company for the Q3FY25".</description>
</item>
<item>
<title>Press Release Nov 05 2024</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-nov-05-2024-6</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-nov-05-2024-6</guid>
<pubDate>Tue, 05 Nov 2024 21:43:57 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated November 05, 2024, titled "Press Release".</description>
</item>
<item>
<title>Press Release Oct 23 2024</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-oct-23-2024-3</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-oct-23-2024-3</guid>
<pubDate>Thu, 24 Oct 2024 01:24:27 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated October 23, 2024, titled "Mankind Pharma Completes Landmark Acquisition of BSV".</description>
</item>
<item>
<title>Press Release Jul 31 2024</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-jul-31-2024-4</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-jul-31-2024-4</guid>
<pubDate>Wed, 31 Jul 2024 19:08:26 GMT</pubDate>
<description>Press Release on Financial Results of the Company for the quarter ended on June 30, 2024.</description>
</item>
<item>
<title>Press Release Jul 25 2024</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-jul-25-2024-4</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-jul-25-2024-4</guid>
<pubDate>Fri, 26 Jul 2024 01:08:24 GMT</pubDate>
<description>Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Mankind Pharma to acquire 100% stake in BSV .</description>
</item>
<item>
<title>Press Release May 15 2024</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-may-15-2024-2</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-may-15-2024-2</guid>
<pubDate>Wed, 15 May 2024 23:35:19 GMT</pubDate>
<description>Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results for the quarter and financial year ended on March 31, 2024.</description>
</item>
<item>
<title>Press Release Mar 11 2024</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-mar-11-2024-1</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-mar-11-2024-1</guid>
<pubDate>Mon, 11 Mar 2024 19:23:44 GMT</pubDate>
<description>Mankind Pharma Limited has informed the Exchange regarding a press release dated March 11, 2024, titled "AstraZeneca Pharma India Ltd and Mankind Pharma partner to accelerate access to asthma medicine for patients in India".</description>
</item>
<item>
<title>Press Release Jan 31 2024</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-jan-31-2024-7</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-jan-31-2024-7</guid>
<pubDate>Wed, 31 Jan 2024 23:08:01 GMT</pubDate>
<description>Press Release on Financial Results for the quarter and nine months ended December 31, 2023.</description>
</item>
<item>
<title>Press Release Oct 31 2023</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-oct-31-2023-5</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-oct-31-2023-5</guid>
<pubDate>Tue, 31 Oct 2023 21:57:35 GMT</pubDate>
<description>Press Release on Financial Results for the quarter and half year ended September 30, 2023</description>
</item>
<item>
<title>Press Release Aug 02 2023</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-aug-02-2023-3</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-aug-02-2023-3</guid>
<pubDate>Wed, 02 Aug 2023 23:24:05 GMT</pubDate>
<description>Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results for the quarter ended June 30, 2023 .The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com.You are requested to kindly take the above information on your records.</description>
</item>
<item>
<title>Press Release May 30 2023</title>
<link>https://6ix.com/company/mankind-pharma-ltd/news/press-release-may-30-2023-4</link>
<guid isPermaLink="true">https://6ix.com/company/mankind-pharma-ltd/news/press-release-may-30-2023-4</guid>
<pubDate>Tue, 30 May 2023 23:21:05 GMT</pubDate>
<description>Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), please find enclosed herewith the Press Release on Financial Results of the Company for the quarter and financial year ended on 31st March 2023.</description>
</item>
</channel>
</rss>